Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis

Table 2 Comparative studies evaluating the effectiveness of radiotherapy in unresectable advanced hepatocellular carcinoma

Ref.	Subject	Study aim	n	1 yr PFS	OS	P value
Eun et al[83]	BCLC C/D	RT vs BSC	29 vs 18	-	45.9 vs 4.8	< 0.001
Yoon et al[35]	Locally advanced	CCRT vs others	106 vs 106	-	11.4 vs 6.6	0.02
Cho et al[27]	BCLC C	TACE + RT vs sorafenib	67 vs 49	-	14.1 vs 3.3	< 0.001
Nakazawa et al[28]	HCC with PVTT	RT vs sorafenib	28 vs 28	-	10.9 vs 4.8	0.002
Li et al[33]	HCC with PVTT	TACE + RT vs TACE	108 vs 108	-	10.9 vs 4.1	< 0.001
Guo et al[23]	Large HCC	TACE + RT vs TACE	89 vs 76		1-yr (%) 64.0 vs 39.9	< 0.001
Tang et al[26]	HCC with PVTT	RT vs surgery	185 vs 186	32.3% vs 42.2%	1-yr (%) 51.6 vs 40.1	0.03
Shiozawa et al[31]	≤ 5-cm solitary HCC	SABR vs RFA	35 vs 38	86.1% vs 85.6%	1-yr (%) 95.2 vs 100	0.08
Wahl et al[34]	Inoperable localized	SABR vs RFA	63 vs 161	LC 97.4% vs 83.6%	1-yr (%) 74.1 vs 69.6	NS

BCLC: Barcelona Clinic Liver Cancer; BCS: Best supportive care; CCRT: Concurrent chemoradiotherapy; HCC: Hepatocellular carcinoma; NS: Not significant; OS: Overall survival; PFS: Progression-free survival; PVTT: Portal vein tumor thrombosis; RFA: Radiofrequency ablation; RT: Radiotherapy; SABR: Stereotactic body radiotherapy; TACE: Trans-catheter arterial chemoembolization.